Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) announced its quarterly earnings data on Monday. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD Phase II results are expected in November 2026, with primary iADRS results, CDR-SB and other secondary outcomes, safety data, and imaging and fluid biomarker results. Management views the trial as a potential foundation for a registration package and a subsequent single confirmatory Phase III study.
• Management identified approximately 30% slowing on iADRS over 18 months as the efficacy benchmark for advancing sabirnetug, while anticipating low-double-digit ARIA-E rates. The 12-month open-label extension has more than 95% rollover but is expected to generate data into 2027 rather than be included in the initial top-line readout.
• Acumen reported encouraging preclinical results for its enhanced brain delivery program, including up to 40-fold greater frontal-cortex exposure for ACU401 in non-human primates while preserving A-beta oligomer selectivity and a clean hematological profile. The company is advancing ACU301 and ACU401 toward an IND filing expected in mid-2027.
• Acumen ended the quarter with approximately $79 million in cash and marketable securities, which management expects to fund current operations only into early 2027. Third-quarter net loss was $25.4 million, including $21.1 million in R&D expenses, indicating likely future financing needs depending on clinical results and development plans.

Acumen Pharmaceuticals Price Performance

Shares of ABOS opened at $2.26 on Wednesday. The stock has a market capitalization of $163.44 million, a PE ratio of -1.47 and a beta of 0.33. The business’s fifty day moving average price is $2.49 and its 200 day moving average price is $2.50. Acumen Pharmaceuticals has a 12-month low of $1.50 and a 12-month high of $3.60.

Wall Street Analyst Weigh In

ABOS has been the subject of a number of research reports. Citigroup lifted their price target on shares of Acumen Pharmaceuticals from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of Acumen Pharmaceuticals in a research note on Wednesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday, October 2nd. Wall Street Zen cut shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acumen Pharmaceuticals in a research report on Thursday, September 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Acumen Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s research centers on amyloid beta oligomers, toxic protein assemblies that Acumen believes contribute to the development and progression of Alzheimer’s disease.

Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers.